BIIB015

DB06304InvestigationalProtein Based Therapies

BIIB015 is a humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, anti-cripto, monoclonal antibody. It has been investigated for the treatment of subjects with relapsed or refractory solid tumours.

Mechanism: Pharmacologically active on Protein Cripto
Curator reviewed
Primary indication: Investigated for use/treatment in solid tumors.Curator reviewed
Also known as: Anti-Cripto-DM4
Code names: BIIB015

Resolves to

Targets

P13385CRIPTO

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with BIIB015, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account